How CDMOs Are Contributing To The Ongoing Future Of Medicine — A Conversation With Nick Maragos Of Northway Biotech The BluEPrint By Executive Platforms podcast

39:01

In the run-up to the 2025 edition of the North American Sustainability & Responsibility Summit series we spoke with Jessica Monserrate and Jordan Keller of BASF, a 150-year-old chemical company with 111,000 employees working in 230 production and R&D sites in 90 countries. BASF is committed to ambitious sustainability targets, including a 25% reduction in Scope 1 and 2 greenhouse gas emissions by 2030 and achieving net zero across all scopes by 2050. In this wide-ranging conversation, we explore how BASF is driving sustainability, which role renewable carbon plays, the importance of mass balance and agriculture, and how all of these efforts can provide significant benefits to both customers and the environment. For all this and more, give this episode a listen! -- Jessica Monserrate Head of Sustainability Agricultural Solutions, NA BASF Jessica has 10 years’ experience in R&D, most recently serving as Head of Microbiome Discovery and Head of Trait Engineering driving new lead discovery and improvement for Trait Research in Pest, Herbicide and Disease Control. During this time, she led the operation to manage and screen BASF’s 100,000 microbial strain collection looking for input traits and natural product chemistries for a variety of research projects. Prior to this she led the Mode of Action team for Bater as well as several global projects related to scouting for new bio-based solutions for pest control, and worked with VC fluids for the creation of new start-ups. Jessica earned her Doctorate in Genetics, Cell Biology and Biochemistry from the University of California, Irvine followed by a post doctorate at Duke University studying small molecule and protein interactions. Her passion is to apply scientific innovation in solving the world’s greatest challenges and proudly represents BASF’s commitment to sustainability. Jordan Keller Head of Renewable Carbon NA BASF Renewable Carbon (BReC) Jordan Keller joined BASF twelve years ago as an engineer and has held roles of growing responsibility ever since. Today she is the Head of Renewable Carbon for North America, after more than two years as the Senior Manager Biomass Balance Solutions North America. Jordan graduated from the University of Texas in 2013 with a degree in chemical engineering and now works for BASF in Houston. -- BASF is a global chemical company that combines economic success with environmental protection and social responsibility. The company has around 112,000 employees in more than 90 countries, managing over 230 production sites, including 6 Verbund sites. In the United States, BASF runs over 100 production and research and development (R&D) facilities. The company boasts a diverse portfolio of more than 45,000 products for the segments Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care, and Agricultural SolutionsIn 2023, BASF reported a turnover of 68.9 billion euros. BASF is committed to ambitious sustainability targets, including a 25% reduction in Scope 1 and 2 greenhouse gas emissions by 2030 and achieving net zero across all scopes by 2050. In terms of the circular economy, BASF is committed to decoupling growth from resource consumption. The company aims to generate sales of € 10 billion from Loop Solutions for our customers by 2030 (2023: €5 billion). This encompasses revenue from circular products, which are based on renewable or recycled materials or support the recycling process (close the (close the loop), as well as products that increase the durability or prolong the lifespan of materials (extend the loop).…

The bluEPrint by Executive Platforms

1
How Medical Device Companies and CDMOs are Partnering Together to Drive Innovation and Serve Patients Better 21:12

8 weeks ago21:12

21:12

In the run-up to the 2025 edition of the Medical Device Manufacturing Excellence Summit series we spoke with Shawn McCarthy, Jessica Swanson, and Peggy Hansen of Regenity Biosciences about exciting developments in the Medical Device space, with a particular emphasis on both the power of collaboration and the importance of a regulatory strategy. Regenity is an industry-leading CDMO working with 120 different industry partners and offering special expertise in regenerative devices. In this wide-ranging conversation we talk about industry trends, how medical device manufacturers are evolving to continue to meet the needs of patients, and also about some of the big ideas Regenity wants to share with the executives attending MDMES25. For all this and more, give this episode a listen! -- Regenity Biosciences, a Linden Capital Partners portfolio company, is a leading global developer and manufacturer of bioresorbable technologies to repair and regenerate natural tissue and bone for a variety of markets including dental, spine, orthopedic, sports medicine, advanced wound, neurosurgery, ENT, and nerve repair. Founded in 1997, Regenity (formerly Collagen Matrix, Inc.) is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Regenity’s product portfolio includes a variety of collagen-based and synthetic polymer solutions that support the company’s platform for tissue and bone regeneration. Regenity develops proprietary products that are sold to OEM customers on either a contract or private label basis and offers partnership opportunities including contract product development and manufacturing services. For more information, please visit www.regenity.com .…

The bluEPrint by Executive Platforms

1
The Ctrl-Alt-Speech Podcast — A Conversation with Mike Masnick and Ben Whitelaw 38:03

11 weeks ago38:03

38:03

There is a podcast Executive Platforms would like to bring to the attention of our network of senior executives. For everyone interested in online speech, especially issues like trust and safety, content moderation, regulations and compliance, and how technology is changing the way people engage with one another, we recommend the Ctrl-Alt-Speech Podcast co-hosted by Techdirt’s Mike Masnick and Everything in Moderation’s Ben Whitelaw. In this episode we talk about how the podcast came to be, what it hopes to do to help people navigate the evolving landscape of online speech, and what business leaders especially should be thinking about and learning about to prepare their organizations for a new and changing reality, with all that means for the future of commerce. For all this and more, give this episode a listen! Mike Masnick Co-Host, Ctrl-Alt-Speech Podcast CEO and Founder, Techdirt Ben Whitelaw Co-Host, Ctrl-Alt-Speech Podcast Editor, Everything in Moderation…

The bluEPrint by Executive Platforms

1
Where Cell and Gene Therapies are Going — A Conversation with Diluks De Silva of Compliance Architects 14:47

12 weeks ago14:47

14:47

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Diluks de Silva to talk about Cell and Gene Therapies. For many years we have been hearing these and other Advanced Therapy Medicinal Products (ATMPs) are moving towards commercialization, and each individual therapy that has been approved is heralded as a pioneer to be celebrated and studied for lessons learned and best practices. This year something like 40 cell and gene therapies came to market, and by every indication this is just the start of a whole new generation of medicine about to help patients around the world. What does that look like on the ground? What is the industry doing to prepare itself for what comes next? How do you control things like cost and scalability while you are still inventing how to manufacture the new therapies in the first place? How are these innovations pairing with medical devices, and what does that mean for the future of medicine? There is so much good work being done, and so much still to do. As always, the experts at Compliance Architects have a comprehensive understanding of where the industry is, where it is going, and what needs to happen to ensure everyone’s success. For everyone looking for the updates that matter most on this exciting frontier of medicine, give this episode a listen! -- Diluks De Silva Vice President Compliance Architects LLC -- Compliance Architects LLC Compliance Architects LLC delivers high-value compliance, quality, and regulatory consulting services to companies directly regulated by the U.S. FDA and other global regulatory authorities. With capabilities ranging from quality systems implementations to audits, inspection readiness, enforcement remediation, and outsourced compliance services, Compliance Architects LLC has the experience, expertise, and delivery capability to significantly improve your company’s business outcomes. Jack Garvey is CA’s founder and CEO, a chemical engineer and a practicing regulatory attorney, and has spent his entire career helping companies navigate the challenges at the intersections of science, engineering, business, and law.…

The bluEPrint by Executive Platforms

1
Hari Pujar of Tessera Therapeutics & Flagship Pioneering — The Future of Medicine 15:40

13 weeks ago15:40

15:40

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Hari Pujar of Tessera Therapeutics and Flagship Pioneering to offer a concise but still in-depth look at the present and future of biopharmaceutical manufacturing, especially as it relates to Advanced Therapy Medicinal Products (ATMPs). Incredible progress has been made and is being made, but of course there are bottlenecks to be addressed as the industry grows, and as these new treatments become commercially available, the issue of cost comes into sharp focus. Where does the industry find itself today, and what are its plans for tomorrow? Give this interview a listen for a terrific window into the state of an industry on the cusp of an incredibly bright future. -- Hari Pujar Chief Operating Officer & Operating Partner Tessera Therapeutics & Flagship Pioneering Hari is a biopharmaceutical executive with experience in vaccine, biologics, mRNA, small molecule, gene therapy modalities, with a passion for value creation. He has enterprise-wide experience including platform and product development, cGMP manufacturing, and commercial, with geographies spanning North and South America, Europe, and Asia.…

The bluEPrint by Executive Platforms

1
Martin Müller & Søren Thuesen Pedersen of Novo Nordisk — Collaboration Among Industry Peers to Move the Life Sciences Forward 24:05

13 weeks ago24:05

24:05

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Martin Müller and Søren Thuesen Pedersen of Novo Nordisk to talk about opportunities biopharmaceutical manufacturers have to work together to lower costs, standardize equipment, build win-win scenarios for procurement and supply chain, and similar initiatives where competitive advantage and IP are not at stake, but costs and compliance and other performance metrics can be improved through joining forces and agreeing on things collectively rather than each company having to reinvent its own wheel on every issue. Building upon their earlier presentation that covered much of the same content, we discuss what would that collaboration look like in real terms? What does getting started look like, and how can interested companies join the ongoing conversations and deliberations? For all that and more, give this episode a listen! -- Martin Müller Director Technology Development - AMSAT - Technology Innovation Novo Nordisk Martin P. Müller joined Novo Nordisk in 2014 and currently directs development projects for innovative technologies within Aseptic Manufacturing, with particular focus on formulation, filling, wash & sterilization, and environmental monitoring. Before moving to production in Novo Nordisk, Mr. Müller has served 10 years in Device R&D, driving the digital agenda of the area, external affairs and QMS-processes and project management, among others. Mr. Müller earned his Master of Arts from Humboldt University Berlin, Germany, and his Master of Business Administration from Copenhagen Business School, Denmark. Søren Thuesen Pedersen Senior Director, External Affairs Regulatory Policy and Intelligence Novo Nordisk Søren Thuesen Pedersen is Senior Director, External Affairs, Regulatory Policy and Intelligence at Novo Nordisk. He is a Chemical Engineer by education and has been working 30 years in Novo Nordisk. During that that time he has been engaged and lead different areas within Manufacturing, QC-Laboratory and CMC Manufacturing Development. He has been one of the founding fathers of the Novo Nordisk External Requirements’ Process; How does Novo Nordisk ensure compliance of new external requirements? Mr. Pedersen is currently responsible for the External Representation and Advocacy strategy out of Novo Nordisk’s GMP&Q area and represents Novo Nordisk in various associations ISPE, EFPIA, IFPMA and BIO. Specifically, Mr. Pedersen is a member of the EFPIA Manufacturing Quality Expert Group (MQEG) since 2019 and member of the Board of Directors in IQ Consortium. He has furthermore been member of the Novo Nordisk Board of Directors for 12 years as an elected employee representative. His spare time interests include Danish and EU Politics.…

The bluEPrint by Executive Platforms

1
The Speaker Roundtable from BMWS24 — A Conversation About Biopharmaceutical Manufacturing Issues and Ideas 1:05:55

14 weeks ago1:05:55

1:05:55

For this special episode of Executive Platforms' bluEPrint Podcast series we had some of the most senior speakers and delegates from the 2024 edition of the long-running Biomanufacturing World Summit series sit down and speak to the challenges and opportunities submitted by attendees of the event as they filled out their delegate profiles, weighted by popularity. With topics ranging from leadership and culture, to talent attraction, development and retention, to supply chain issues, to commercializing CGTs and other ATMPs, change and disruption throughout the business landscape, and how to serve patients better now and in the future, this wide-ranging conversation sees five senior executives from five very different companies speaking to the issues, ideas, innovations, and inspirations that matter to all of them as guided by a moderator who knows the industry inside and out. It is a fantastic deep dive into what is most relevant to biopharma technical operations leaders today. Give it a listen! Our roundtable panelists are… Moderator: Pascal Bécotte Managing Director Russell Reynolds Panelists: J erry Murry Senior Vice President, Process Development Amgen Tongtong Wang Senior Vice President, Global Head Technical Development Roche Chris Horan Chief Technical Operations Officer Artiva Biotherapeutics Aine Hanly CTO Vir Biotechnology Tina Self Senior Vice President, Global Biologics Manufacturing & Berkeley Site Head Bayer…

The bluEPrint by Executive Platforms

1
AI in Supply Chains: Today's Real-World Applications and What is Still to Come — A Conversation with Experts from Ernst & Young LLP 18:46

14 weeks ago18:46

18:46

At the 2024 edition of the North American Supply Chain Executive Summit series we sat down with two of Ernst & Young LLP’s supply chain leaders to talk about how AI is shaping supply chain operations today, what we can look forward to in the near future, and also where our current use cases are tempering some of the more hyperbolic expectations while also illustrating real-world capabilities that are going to change the way businesses approach data-intensive tasks throughout their value chain and S&OP processes. Takshay Aggarwal and Parag Jategaonkar have more than 45 years of experience between them helping companies bring new technologies into their existing systems and processes, and their enthusiasm for where AI can transform supply chains is palpable. To hear what they have to say, give this episode a listen! -- Takshay Aggarwal EY Americas Supply Chain Growth Platforms Leader Ernst & Young LLP Takshay leads Supply Chain Growth Platforms and Alliances for the EY Americas Supply Chain and Operations practice. Takshay brings over 20 years of end-to-end supply chain experience in consumer products, retail, automotive, industrial and life sciences. He’s helped companies transform their operating models to provide better customer experiences and improve their productivity by leveraging technology and artificial intelligence capabilities using cloud and platform approaches. Takshay helps clients gain a competitive advantage via digital and analytics while becoming more agile. Parag Jategaonkar US End to End Supply Chain Strategy and Transformation Leader Ernst & Young LLP Parag is an innovative, people-oriented leader with over 25 years of management consulting experience helping clients improve business performance and achieve their goals. -- Ernst & Young LLP In Consulting, we are building a better working world by transforming businesses through the power of people, technology and innovation. The diversity and skills of 70,000+ people will help clients realize transformation by putting humans at the center, delivering technology at speed and leveraging innovation at scale. www.ey.com/en_gl…

The bluEPrint by Executive Platforms

1
How CDMOs are Contributing to the Ongoing Future of Medicine — A Conversation with Nick Maragos of Northway Biotech 11:57

14 weeks ago11:57

11:57

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Nick Maragos of Northway Biotech to talk about how biopharmaceutical manufacturers are increasingly partnering with CDMOs to advance the future of medicine, how that working relationship is evolving over time, and what CDMOs need to do to continue to grow and meet the needs of the industry. With special reference to Northway Biotech’s own example, Nick talks about how companies can ensure they are compatible, what the working relationship needs to be, and what factors need to be included in any informed decision-making before and during a partnership. Give this episode a listen! -- Nick Maragos VP Business Development Northway Biotech -- Northway Biotech Northway Biotech is an end-to-end biologics contract development and manufacturing organization (CDMO) supporting customers worldwide. The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania and Waltham, Mass., U.S.…

The bluEPrint by Executive Platforms

1
‘First in Human’ Continuous Manufacturing in Biopharmaceuticals — A Conversation with Magnus Schroeder of Just – Evotec Biologics 10:52

14 weeks ago10:52

10:52

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Magnus Schroeder, the VP, Process & Product Design for Just – Evotec Biologics, to talk about some of the advantages of continuous manufacturing in biopharmaceutical manufacturing, especially for companies whose products are approaching the First in Human (FIH) stage. It is never too early to think about process optimization, scalability, and controlling costs, but there is an understandable position where companies focused on the medicine and the science believe that can be sorted out later. Just – Evotec Biologics is a passionate advocate for taking lessons from other industries that build their businesses’ success into the R&D stage of their products’ development. So what does that look like in the Life Sciences? What role do CDMOs need to play to help the industry succeed at this, especially at the crucial FIH stage? For all this and more, give this episode a listen! -- Magnus Schroeder VP, Process & Product Design Just – Evotec Biologics -- Just – Evotec Biologics , wholly owned by Evotec SE, is a CDMO offering development and manufacturing services for antibody, next-generation biologics, and biosimilar products. We collaborate with partners starting from antibody discovery through process development and manufacturing with sites in US and Europe. We designed our technologies to reduce cost of goods and help expand global access to affordable high-quality biotherapeutics. Our team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics.…

The bluEPrint by Executive Platforms

1
John H. Adams, Jr. of Spark Therapeutics — Computer Software Assurance for Biopharmaceutical Manufacturers 14:33

14 weeks ago14:33

14:33

At the 2024 edition of the Biomanufacturing World Summit series we sat down with John H. Adams, Jr., Spark Therapeutics’ Senior Director, Validation, to talk about Computer Software Assurance in the Life Sciences. John has been doing Computer Systems Validation (CSV) for decades as a regulatory requirement, so when talk of a risk-based Computer Software Assurance (CSA) requirement started making the rounds, he was interested to understand the differences so he could best stay ahead of the compliance curve and ensure his best practices were not out of step with expectations. In this episode, John walks us through where the conversation between industry and regulators currently stands, what validation professionals should already be doing, what they should continue to do, what they should confirm they are doing correctly, and what they should prepare themselves for if and when current guidance becomes new regulations. For everyone in the Life Sciences who cares about the compliance of manufacturing systems, give this episode a listen! -- John H. Adams, Jr. Senior Director, Validation Spark Therapeutics In his current role as the Senior Director of Validation at Spark, John leverages over 24 years of expertise in the compliance and validation of enterprise computer systems, applications, and equipment regulated by the FDA and EU. John is a compliance and validation thought leader and has a deep understanding of 21 CFR Parts 210, 211, 606, 820, 11, and Annex 11. John’s experience spans a variety of analytical systems, including HPLCs and spectrophotometers, as well as computer systems such as ERP, LIMS, EDMS, EMS, PCS, and DCS, serving major pharmaceutical, medical device, and blood management companies. Before joining Spark in May of 2015, his career included roles at Pfizer, AstraZeneca, TEVA, Smith & Nephew, GE Healthcare, DSM, Haemonetics, and the American Red Cross, where he has consistently ensured compliance with predicate rules, 21 CFR Part 11, and GAMP 5 guidance. John holds a Bachelor of Science degree in Computer Information Systems from the Florida Institute of Technology.…

The bluEPrint by Executive Platforms

1
The TechOps Leadership Accelerator Program — A Conversation with Pascal Bécotte and Laurent Rossi 21:49

15 weeks ago21:49

21:49

At the 2024 edition of the Biomanufacturing World Summit series Pascal Bécotte of Russell Reynolds and Laurent Rossi, the former CEO of the F1 team Alpine and a former Google Executive, spoke about Peak Performance Leadership . In this follow-up interview they explain some of the origins and themes behind that presentation, and then launched into details of the TechOps Leadership Accelerator Program first outlined in an interview at PMWS23 . How can biopharmaceutical manufacturers address the generational gap in leadership for technical operations roles that will need to be filled as Advanced Therapy Medicinal Products (ATMPs) begin to commercialize and scale? For updates on how the industry collectively is working to address this critical bottleneck to growth, give this episode a listen! -- Pascal Bécotte Managing Director Russell Reynolds Pascal leads Russell Reynolds’ operations in New York and Canada. He works closely with our healthcare clients around the globe, advising them on their talent strategy, including leadership assessment, succession planning, and the recruitment of directors, CEOs, and other senior executives. Within the healthcare industry, Pascal specializes in biotech and pharma technical operations, including process development, manufacturing, quality, engineering, and supply chain leadership. Pascal received his Bachelor of Engineering Physics degree from the Royal Military College of Canada and trained as an aerospace engineer with the Royal Canadian Air Force. He also earned master’s and doctorate degrees in business administration from Athabasca University in Canada, where he focused his research and dissertation on CEO succession. Pascal speaks fluent French and English. Laurent Rossi Former Chief Executive Officer Alpine (F1) and Google Executive Laurent Rossi serves as a senior advisor to the Renault Group and is the former Chief Executive Officer of Alpine Racing SAS and chairman of Alpine Racing Ltd. Rossi previously served as Renault’s Chief Strategy Officer and was appointed CEO in 2021 with the Alpine name joining the Formula 1 grid ahead of the 2021 FIA Formula 1 World Championship season. He began his career at Renault in Paris before earning his MBA from Harvard Business School and joining Boston Consulting Group, where he worked in the New York office. As an automotive expert, he was a consultant on several strategic and operational assignments, working with major global automakers and parts suppliers. He covered the entire value chain from design to sales, including powertrain strategy, manufacturing, and supply chain. In 2012, he moved to Google, taking charge of developing commercial relations with major automotive industry companies, initially based in Paris for the Europe region, then in New York for the Americas region. Rossi eventually served as the head of Google’s Global Auto Practice, before returning to Renault in February 2018. After a short period heading the Organization Department, he was appointed as VP of Corporate Strategy and Business Development. Rossi holds a Master of Science in Fluid Mechanics from ENSEEIHT (Toulouse) and a Master of Science in Mechanical Engineering / Automotive Engines & Petroleum Products from IFP School. -- Russell Reynolds Associates is a global search and leadership advisory firm. Our 425+ consultants in 46 offices work with public, private and nonprofit organizations across all industries and regions. We help our clients build teams of transformational leaders who can meet…

The bluEPrint by Executive Platforms

1
How Technology Fits into the Larger Conversation of Change in the Manufacturing Sector — A Conversation with Sathish Thirmoorthy of UCBOS 14:19

17 weeks ago14:19

14:19

At the 2024 edition of the North American Food Manufacturing Summit series we sat down with Sathish Thirmoorthy, the Chief Strategy Officer of UCBOS, to put into context how the new generation of technologies available to manufacturers are shaping how organizations function and evolve, especially in the current age of disruption. Far too often we focus on the incredible new capabilities unlocked by emerging tools, but it is important to remember that technology in the manufacturing space at its heart is about helping people do more with less, do things faster, and do things right the first time every time. How should Manufacturers combine their successes across different processes into one platform that coordinates, communicates, and consolidates these disparate systems into a larger whole to help the business move forward? What does that look like in real terms, and how can manufacturers take the fear factor out of embracing further change? For all this and more, give this episode a listen! -- Sathish Thirumoorthy Chief Strategy Officer UCBOS Inc. Sathish Kumar Thirumoorthy has an extensive background in enterprise services, supply chain consulting, and IT consulting. With experience in companies such as ITOrizon Inc., Oracle, CGI, and Hewlett Packard Enterprise, Sathish has held roles ranging from Senior Support Consultant to Director, Consulting and Practice Leader. Sathish’s expertise focuses on consulting, solutioning, presales pursuits, and client relationship management across various industry verticals. Sathish's career has been marked by strategic leadership, solution-based project delivery, and proactive proposal development to drive business growth and enable transformation for global clients. -- UCBOS Inc. Pioneering Zero Code Transformation UCBOS, Inc. (“You See Boss”) is a visionary Zero Code software company based in the USA, committed to revolutionizing digital transformation for enterprises. UCBOS unique approach starts and ends with zero – zero data models, zero code, and most importantly, zero tech debt. UCBOS offers an AI-enabled, zero-code business execution platform that integrates, optimizes, and orchestrates digital processes. Built on 100% No-Code, 100% Metadata, and 100% NoSQL technologies, UCBOS ensures seamless digital integration and a future-ready foundation for enterprise success.…

The bluEPrint by Executive Platforms

1
The Speaker Roundtable from NAFMS24 — A Conversation About Food Manufacturing Issues and Ideas 49:12

18 weeks ago49:12

49:12

At Executive Platforms’ North American Food Manufacturing Summit , two of our keynote speakers and one of our leading solution-providers sat down to record a special episode of the BluEPrint Podcast series reviewing the top-of-mind issues and ideas of food manufacturing executives today as chosen by the NAFMS24 attendees, weighted by popularity. With topics ranging from process optimization, to digital transformation and artificial intelligence, to controlling costs, building and maintaining culture, supporting growth, workforce development, sustainability, and much more, this is a conversation that should be of interest to every food and beverage manufacturer working today. Give it a listen! This roundtable includes… Moderator: Sudhir Arni SVP, Business Outcomes Sight Machine Panelists: Josh Chou Chief Supply Chain Officer McCormick & Company Sarvi Bajwa SVP Manufacturing Danone -- Sight Machine Sight Machine drives rapid increases in manufacturing productivity. Our technology platform delivers real outcomes in efficiency, sustainability and quality—in weeks. Manufacturers that deploy Sight Machine empower teams to better collaborate, innovate and accelerate their journey of continuous productivity improvement. Founded by a team with deep manufacturing expertise, Sight Machine has offices in San Francisco and Ann Arbor, Mich.…

The bluEPrint by Executive Platforms

1
AI’s Place in the Future of the Food and Beverage Industry’s Supply Chain and Manufacturing Operations — A Conversation with Jeremy Tancredi and Randal Kenworthy of West Monroe 29:01

18 weeks ago29:01